Safety of Recombinant Human Factor IX, Nonacog Alfa, for Usual Use In Pediatric Patients: Results From a Prospective Registry of European Hemophilia B Patients

被引：0

作者：

Rendo, Pablo ^{[1
]}

Berntorp, Erik ^{[2
]}

Keeling, David M. ^{[3
]}

Makris, Michael ^{[4
]}

Hermans, Cedric R. ^{[5
]}

Mauser-Bunschosten, Ereline Pauline ^{[6
]}

Musso, Roberto ^{[7
]}

Tagliaferri, Annarita ^{[8
]}

Kollmer, Carl

Baumann, James

Charnigo, Robert

机构：

[1] Pfizer, Clin Affairs, Collegeville, PA USA

[2] Malmo Univ Hosp, Dept Clin Sci, Malmo, Sweden

[3] Oxford Haemophilia & Thrombosis Ctr, Oxford, England

[4] Sheffield Teaching Hosp Trust, Dept Haematol, Sheffield, S Yorkshire, England

[5] Clin Univ St Luc, B-1200 Brussels, Belgium

[6] Univ Medich Ctr Utrecht, Utrecht, Netherlands

[7] Azienda Osped Ferrarotto, Catania, Italy

[8] Osped Maggiorore, Ctr Emostasi & Curaemofilia, Parma, Italy

来源：

BLOOD | 2010年 / 116卷 / 21期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1504 / 1504

页数：1

共 50 条

[1] SAFETY OF BeneFIX® (NONACOG ALFA, RECOMBINANT HUMAN FACTOR IX) FOR USUAL USE IN PEDIATRIC PATIENTS: RESULTS FROM A PROSPECTIVE REGISTRY OF EUROPEAN HEMOPHILIA B PATIENTS
Rendo, Pablo
Berntorp, Erik
[J]. PEDIATRIC BLOOD & CANCER, 2010, 54 (06) : 811 - 811
[2] A prospective registry of European haemophilia B patients receiving nonacog alfa, recombinant human factor IX, for usual use
Berntorp, E.
Keeling, D.
Makris, M.
Tagliaferri, A.
Male, C.
Mauser-Bunschoten, E. P.
Musso, R.
Roca, C. A.
Hassoun, A.
Kollmer, C.
Charnigo, R.
Baumann, J.
Rendo, P.
[J]. HAEMOPHILIA, 2012, 18 (04) : 503 - 509
[3] Evaluation of the safety and efficacy of recombinant factor IX (nonacog alfa) in minimally treated and previously treated Chinese patients with hemophilia B
Renchi, Y.
Zhao, Y.
Wang, X.
Sun, J.
Jin, J.
Wu, D.
Charnigo, R.
O'Brien, A.
Rendo, P.
Zhong, Z.
[J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2011, 9 : 356 - 356
[4] Postmarketing safety and effectiveness of recombinant factor IX (nonacog alfa) in Japanese patients with haemophilia B
Fukutake, Katsuyuki
Taki, Masashi
Matsushita, Tadashi
Sakai, Michio
Takata, Ami
Yamaguchi, Hiromi
Karumori, Toshiyuki
[J]. HAEMOPHILIA, 2019, 25 (04) : E247 - E256
[5] Evaluation of the Safety, Efficacy of Recombinant Factor IX (nonacog alfa) in Japanese Patients with Hemophilia B-Interim Result of Post Marketing Surveillance Study
Suzuki, Takashi
Fukutake, Katsuyuki
Amano, Kagehiro
Hanabusa, Hideji
Taki, Masashi
Matsushita, Tadashi
Shima, Midori
Sakai, Michio
Iizuka, Masahiro
Shibasaki, Yoshiyuki
[J]. BLOOD, 2012, 120 (21)
[6] SAFETY AND EFFICACY OF RECOMBINANT FACTOR IX FUSION PROTEIN IN PEDIATRIC PATIENTS WITH HEMOPHILIA B
Chambost, Herve
Drelich, Douglass
Seifert, Wilfried
Castaman, Giancarlo
[J]. PEDIATRIC BLOOD & CANCER, 2023, 70 : S175 - S175
[7] Population pharmacokinetic modeling of factor IX activity after administration of nonacog alfa in patients with hemophilia B
Korth-Bradley, Joan M.
Suzuki, Akiyuki
Tomono, Yoshiro
[J]. HAEMOPHILIA, 2016, 22 : 102 - 102
[8] Successful use of recombinant factor IX concentrate (Nonacog-alfa, benefix®) in two patients with severe hemophilia B and total knee replacement (TKR)
Gerhardt, Andrea
Stahlschmidt, Kristina
Ilg, Ansgar
Scharf, Rudiger E.
Zotz, Rainer B.
[J]. BLOOD, 2007, 110 (11) : 54B - 54B
[9] Successful use of recombinant factor IX (rFIX, nonacog-alfa, Benefix) in two patients with severe hemophilia B and total knee replacement (TKR)
Gerhardt, A.
Stahlschmidt, K.
Zotz, R.
Krauspe, R.
Scharf, R.
Ilg, A.
[J]. HAEMOPHILIA, 2008, 14 : 11 - 11
[10] Evaluation of the safety and efficacy of recombinant Factor IX (nonacog alfa) in Japanese patients with hemophilia B - The second interim analysis of 304 patients in a post-marketing surveillance study
Amano, Kagehiro
Fukutake, Katsuyuki
Hanabusa, Hideji
Taki, Masashi
Matsushita, Tadashi
Shima, Midori
Sakai, Michio
Yamaguchi, Hiromi
Karumori, Toshiyuki
[J]. HAEMOPHILIA, 2014, 20 : 22 - 22

← 1 2 3 4 5 →